“…Experiments using in utero gene delivery methods are usually performed on mid- to late-gestational fetuses (from E9–18), probably because they are relatively easier to be identified by visual observation and also can be used in basic research on in utero gene therapy [ 15 ]. All these experiments were based on the opening of the abdominal portion of an anesthetized pregnant animal, exposure of uterine horns, and injection of a solution into a specific site of a fetus [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ] or its surrounding or associated tissues, such as placenta [ 30 , 31 , 32 ], amniotic cavity [ 13 , 14 , 26 , 33 , 34 , 35 ], and the yolk sac (YS) [ 36 ], using a glass micropipette (shown in Figure 1 B). The solution contains viral vectors (including recombinant adeno-associated viruses (rAAVs), lentiviruses, adenoviruses (Ad)), or nonviral vectors (including plasmid DNA).…”